Humoral immunity in the Friend retrovirus infection model

Halemano, Kalani; Harper, Michael S.; Guo, Kejun; Li, Sam X.; Heilman, Karl J.; Barrett, Bradley S.; Santiago, Mario L.

doi:10.1007/s12026-012-8370-y

Cited by 17 publications

(23 citation statements)

References 100 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected, mA3 ϩ/s antisera had significantly higher NAb titers using a previously described in vitro NAb assay (Fig. 1B) (12,14,15). Antisera were pooled at equal volumes, and 3 l of pooled antisera was coincubated with 140 SFFU of FV in 300 l for 1 h at 37°C prior to administration in susceptible BALB/c mice.…”

supporting

confidence: 81%

Requirement for Fc Effector Mechanisms in the APOBEC3/Rfv3-Dependent Neutralizing Antibody Response

Halemano

Barrett

Heilman

et al. 2015

J Virol

Self Cite

View full text Add to dashboard Cite

Antiretroviral neutralizing antibody (NAb) responses are often evaluated in the absence of Fc-dependent immune effectors. In murine Friend retrovirus infection, Apobec3/Rfv3 promotes a potent polyclonal NAb response. Here, we show that the Apobec3/Rfv3-dependent NAb response correlated with virus-specific IgG2 titers and that thein vivoneutralization potency of Apobec3/Rfv3-resistant antisera was dependent on activating Fcγ receptors but not complement. The data strengthen retroviral vaccine strategies aimed at eliciting NAbs that activate specific Fcγ receptors.

show abstract

supporting

confidence: 81%

Requirement for Fc Effector Mechanisms in the APOBEC3/Rfv3-Dependent Neutralizing Antibody Response

Halemano

Barrett

Heilman

et al. 2015

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two types of B-tropic FV were used in this study: (1) an FV stock containing only F-MuLV and SFFV (also referred to as ‘LDV-free FV’ in prior publications); and (2) the classical ‘FV/LDV’ stock containing F-MuLV, SFFV, and a co-infecting endemic RNA virus, Lactate Dehydrogenase-elevating Virus (LDV) (Robertson et al, 2008; Halemano et al, 2013). FV stocks were prepared and titered in BALB/c mice as described (Santiago et al, 2008).…”

Section: Methodsmentioning

confidence: 99%

“…Thus, investigating the role of RNase L in mouse retrovirus infection models may provide insights on the antiretroviral properties of RNase L from a more physiological context. Friend retrovirus (FV) infection of mice represents one of the most well-described in vivo models of retroviral pathogenesis, paving the way for the initial identification of host antiretroviral genes and understanding salient features of retrovirus adaptive immune responses (Nair et al, 2011; Halemano et al, 2013). FV is an ecotropic gammaretrovirus complex that consists of Friend Murine Leukemia Virus (F-MuLV) and Spleen Focus Forming Virus (SFFV) that establishes chronic infection in mice.…”

Section: Introductionmentioning

confidence: 99%

Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection

Barrett

Harper

et al. 2013

Virology

Self Cite

View full text Add to dashboard Cite

Ribonuclease L (RNase L) is a Type I Interferon regulated factor that can significantly inhibit retroviruses in vitro and may activate cytoplasmic sensing pathways to augment adaptive immunity. However, the antiretroviral activity of RNase L remains to be validated in vivo. We investigated the role of RNaseL in counteracting Friend retrovirus (FV) infection relative to a well-described restriction factor, Apobec3. C57BL/6 wild-type (WT) and RNaseL knock-out (KO) mice exhibited similar acute FV infection levels despite significant transcriptional induction of Oligoadenylate Synthetase 1, which produces activators of RNase L. Apobec3 KO mice showed higher FV infection levels relative to WT mice, but deletion of RNaseL in Apobec3 KO mice did not augment FV infection. Moreover, RNaseL did not influence FV-specific IgG responses and recovery from viremia by 28 days post-infection. The results suggest that RNase L is not an evolutionarily-conserved host defense mechanism to counteract retroviruses in vivo.

show abstract

“…Fv1, Fv2, H-2 and Apobec3/Rfv3 govern FV resistance and susceptibility in mice [69, 91]. Fv1 confers a Gag-dependent post-entry block whereas Fv2 confers susceptibility to splenomegaly.…”

Section: Figurementioning

confidence: 99%

Tetherin/BST-2: Restriction Factor or Immunomodulator?

Li¹,

Barrett²,

Guo³

et al. 2016

CHR

Self Cite

View full text Add to dashboard Cite

Cell-mediated immune (CMI) responses are critical for the control of HIV-1 infection and their importance was highlighted by the existence of viral proteins, particularly Vpu and Nef, that antagonize these responses. Pandemic HIV-1 Vpu counteracts Tetherin/BST-2, a host factor that could prevent the release of HIV-1 virions by tethering virions on the cell surface, but a link between Tetherin and HIV-1 CMI responses has not yet been demonstrated in vivo. In vitro, the virological and immunological impact of Tetherin-mediated accumulation of virions ranged from enhanced or diminished cell-to-cell spread to enhanced recognition by virus-specific antibodies for natural killer cell-mediated lysis. However, Tetherin-restricted virions could be internalized through an endocytosis motif in the Tetherin cytoplasmic tail. Given the uncertainties on which in vitro results manifest in vivo and the dearth of knowledge on how Tetherin influences retroviral immunity, in vivo retrovirus infections in mice encoding wild-type, null and endocytosis-defective Tetherin were performed. Here, we highlight results from these in vivo studies suggesting that endocytosis-defective Tetherin functions as a potent innate restriction factor. By contrast, endocytosis-competent Tetherin, the form found in most mammals including humans and the form counteracted by HIV-1 Vpu, was linked to stronger CMI responses in mice. We propose that the main role of endocytosis-competent Tetherin is not to directly restrict retroviral replication, but to promote a more effective CMI response against retroviruses.

show abstract

Humoral immunity in the Friend retrovirus infection model

Cited by 17 publications

References 100 publications

Requirement for Fc Effector Mechanisms in the APOBEC3/Rfv3-Dependent Neutralizing Antibody Response

Requirement for Fc Effector Mechanisms in the APOBEC3/Rfv3-Dependent Neutralizing Antibody Response

Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection

Tetherin/BST-2: Restriction Factor or Immunomodulator?

Contact Info

Product

Resources

About